You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on colorectal cancer.
With genomic and proteomic profiles for more than 100 colon cancer cases, researchers identified drug targets, treatment resistance insights, potential cancer drivers, and more.
Researchers in Nigeria are developing a handheld diagnostic device for identifying high-risk colorectal cancer patients in low-resource environments.
Roche ran a mock clinical trial in which it used DIA mass spec and targeted proteomics to profile 30 colorectal cancer samples under GCP conditions.
Evotec will access Indivumed's IndivuType multi-omics cancer database to discover and develop new precision therapeutics for colorectal cancer.
Research presented at ACMG by Invitae suggests that clinically actionable variants in cancer patients are missed by germline testing that is not done with expanded panels.
As of January the project had returned 290 positive results for CDC Tier 1 conditions from 23,500 participants who had undergone exome sequencing.
The center received a response to its initial submission to the NY State Department of Health in February and will re-submit by the end of this month.
Clinical trials investigating whether epigenetic treatment can restore susceptibility to other treatments are underway in colorectal, lung, and breast cancers.
Clinical researchers at AACR discussed a wide range of approaches focusing on several different potential use-cases in the detection or assessment of early cancers.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.
Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.
A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.
In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.